Jim Mazzola
Contatto Relazioni con gli Investitori presso OUTSET MEDICAL, INC.
Posizioni attive di Jim Mazzola
Società | Posizione | Inizio | Fine |
---|---|---|---|
OUTSET MEDICAL, INC. | Contatto Relazioni con gli Investitori | 01/01/2022 | - |
Storia della carriera di Jim Mazzola
Precedenti posizioni note di Jim Mazzola
Società | Posizione | Inizio | Fine |
---|---|---|---|
CAREFUSION CORPORATION | Contatto Relazioni con gli Investitori | 01/09/2008 | 01/03/2015 |
Public Communications Contact | 01/09/2008 | 01/03/2015 | |
Vendite & Marketing | 01/09/2008 | 01/03/2015 | |
CARDINAL HEALTH, INC. | Public Communications Contact | 01/09/2003 | 01/09/2008 |
CareFusion Foundation | Presidente | - | - |
HALOZYME THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | - | - |
Public Communications Contact | - | - | |
TURG POIN | Contatto Relazioni con gli Investitori | - | - |
Formazione di Jim Mazzola
University of Dayton | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Investor Relations Contact | 4 |
Public Communications Contact | 3 |
Sales & Marketing | 1 |
Settori
Health Technology | 4 |
Distribution Services | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
CARDINAL HEALTH, INC. | Distribution Services |
HALOZYME THERAPEUTICS, INC. | Health Technology |
OUTSET MEDICAL, INC. | Health Technology |
Aziende private | 3 |
---|---|
CareFusion Corp.
CareFusion Corp. Medical DistributorsDistribution Services CareFusion Corp. engages in the manufactures of medical equipment and device. The company was founded on February 4, 2009 and is headquartered in San Diego, CA. | Distribution Services |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
CareFusion Foundation |
- Borsa valori
- Insiders
- Jim Mazzola
- Esperienza